RICHMOND, Calif., April 29, 2026 (GLOBE NEWSWIRE) — Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medication firm, right now introduced that its widespread inventory will transition from buying and selling on The Nasdaq Capital Market to the OTCQB Enterprise Market on Tuesday, Could 5, 2026. This transition follows the receipt by Sangamo of a discover from The Nasdaq Inventory Market LLC indicating that Sangamo’s widespread inventory might be delisted from the Nasdaq Capital Market attributable to non-compliance with Nasdaq’s minimal bid worth requirement. Sangamo intends to request a listening to from Nasdaq to enchantment the delisting willpower. The listening to is not going to keep the suspension of buying and selling of Sangamo’s widespread inventory, and buying and selling of Sangamo’s widespread inventory on The Nasdaq Capital Market is anticipated to be suspended on the open of buying and selling on Could 5, 2026.
Sangamo has secured approval for its widespread inventory to be quoted on the OTCQB Enterprise Market, operated by OTC Markets Group. Sangamo expects its widespread inventory to start buying and selling on the OTCQB Enterprise Market below its present buying and selling image, SGMO, on the open of buying and selling on Tuesday, Could 5, 2026. For quotes or extra info, buyers could go to www.otcmarkets.com.
The transition of buying and selling onto the OTCQB Enterprise Market just isn’t anticipated to lead to materials impacts to Sangamo’s enterprise or operations. Sangamo stays targeted on pursuing alternatives to lift extra capital, together with an evaluation of all strategic choices to maximise the worth of its property, and all through the method has been suggested by a world funding financial institution. Sangamo is presently negotiating a number of potential enterprise growth transactions and expects to share particulars on these potential transactions if and when definitive agreements are executed.
Sangamo will proceed to supply updates on enterprise progress and monetary leads to accordance with relevant Securities and Change Fee rules. Extra info associated to this announcement might be included in a Present Report on Type 8-Okay to be filed with the SEC.
About Sangamo Therapeutics
More Read
Sangamo Therapeutics is a genomic medication firm devoted to translating ground-breaking science into medicines that rework the lives of sufferers and households stricken with severe neurological ailments who don’t have satisfactory or any remedy choices. Sangamo believes that its zinc finger epigenetic regulators are ideally suited to doubtlessly tackle devastating neurological problems and that its capsid discovery platform can increase supply past presently out there intrathecal supply capsids, together with within the central nervous system. Sangamo’s pipeline additionally contains a number of partnered packages and packages with alternatives for partnership and funding. To study extra, go to www.sangamo.com and join with us on LinkedIn.
Ahead-Wanting Statements
This press launch accommodates forward-looking statements primarily based on Sangamo’s present expectations. These forward-looking statements embody, with out limitation, statements referring to Sangamo’s expectations regarding the transition of Sangamo’s widespread inventory to the OTCQB Enterprise Market and the timing and affect thereof, expectations concerning a possible listening to to enchantment Nasdaq’s delisting willpower, Sangamo’s plans to pursue extra alternatives to lift capital and maximize the worth of its property and the potential for execution of definitive agreements in respect of enterprise growth transactions. These statements are usually not ensures of future efficiency and are topic to sure dangers and uncertainties which can be troublesome to foretell. Components that might trigger precise outcomes to vary embody, however are usually not restricted to, dangers and uncertainties associated to Sangamo’s lack of capital assets and wish for substantial extra funding to execute its working plan and to proceed to function as a going concern, together with the danger that Sangamo might be unable to safe a big partnership or different transaction, particularly for its Fabry illness program, offering for substantial upfront funding within the very close to time period essential to fund its operations and function as a going concern; the danger that Sangamo might be unsuccessful in interesting the delisting willpower; the consequences of macroeconomic elements or monetary challenges, together with because of the continued abroad conflicts, tariffs, geopolitical instability, inflation and fluctuations in rates of interest, on the worldwide enterprise setting; the unsure analysis and growth course of, together with the outcomes of medical trials; the regulatory approval course of for product candidates; and the potential for technological developments that obviate applied sciences utilized by Sangamo. Precise outcomes could differ from these projected in forward-looking statements attributable to dangers and uncertainties that exist in Sangamo’s operations and enterprise. These dangers and uncertainties are described extra totally in our Securities and Change Fee filings and reviews, together with in our Annual Report on Type 10-Okay for the yr ended December 31, 2025. Ahead-looking statements contained on this announcement are made as of this date, and Sangamo undertakes no responsibility to replace such info besides as required below relevant regulation.
More Read
Investor Relations and Media Inquiries
